Literature DB >> 10329610

7q31-32 allelic loss is a frequent finding in splenic marginal zone lymphoma.

M Mateo1, M Mollejo, R Villuendas, P Algara, M Sanchez-Beato, P Martínez, M A Piris.   

Abstract

Splenic marginal zone lymphoma (SMZL) has been recognized as an entity defined on the basis of its morphological, phenotypic, and clinical characteristic features. Nevertheless, no characteristic genetic alterations have been described to date for this entity, thus making an exact diagnosis of SMZL difficult in some cases. As initial studies showed that chromosome region 7q22-32 is deleted in some of these cases, we analyzed a larger group of SMZL and other lymphoproliferative disorders that may partially overlap with it. To better define the frequency of 7q deletion in SMZL and further identify the deleted region, polymerase chain reaction analysis of 13 microsatellite loci spanning 7q21-7q36 was performed on 20 SMZL and 26 non-SMZL tissue samples. The frequency of allelic loss in SMZL (8/20; 40%) was higher than that observed in other B-cell lymphoproliferative syndromes (2/26; 7.7%). This difference was statistically significant (P < 0.05). The most frequently deleted microsatellite was D7S487 (5/11; 45% of informative cases). Surrounding this microsatellite the smallest common deleted region of 5cM has been identified, defined between D7S685 and D7S514. By comparative multiplex polymerase chain reaction analysis, we detected a homozygous deletion in the D7S685 (7q31.3) marker in one case. These results suggest that 7q31-q32 loss may be used as a genetic marker of this neoplasia, in conjunction with other morphologic, phenotypic, and clinical features. A correlation between 7q allelic loss and tumoral progression (death secondary to the tumor or large cell transformation) in SMZL showed a borderline statistical significance. The observation of a homozygous deletion in this chromosomal region may indicate that there is a tumor suppressor gene involved in the pathogenesis of this lymphoproliferative neoplasia.

Entities:  

Mesh:

Year:  1999        PMID: 10329610      PMCID: PMC1866606          DOI: 10.1016/S0002-9440(10)65411-9

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  35 in total

1.  Isolation and chromosomal assignment of 100 highly informative human simple sequence repeat polymorphisms.

Authors:  T J Hudson; M Engelstein; M K Lee; E C Ho; M J Rubenfield; C P Adams; D E Housman; N C Dracopoli
Journal:  Genomics       Date:  1992-07       Impact factor: 5.736

2.  Cytogenetic study of B-cell lymphoma of mucosa-associated lymphoid tissue.

Authors:  A C Wotherspoon; L X Pan; T C Diss; P G Isaacson
Journal:  Cancer Genet Cytogenet       Date:  1992-01

3.  Loss of heterozygosity on the long arm of human chromosome 7 in sporadic renal cell carcinomas.

Authors:  V Shridhar; Q C Sun; O J Miller; G P Kalemkerian; J Petros; D I Smith
Journal:  Oncogene       Date:  1997-11-27       Impact factor: 9.867

4.  Genomic imprinting and Igf2 influence liver tumorigenesis and loss of heterozygosity in SV40 T antigen transgenic mice.

Authors:  R Haddad; W A Held
Journal:  Cancer Res       Date:  1997-10-15       Impact factor: 12.701

5.  Allelotype of colorectal carcinomas.

Authors:  B Vogelstein; E R Fearon; S E Kern; S R Hamilton; A C Preisinger; Y Nakamura; R White
Journal:  Science       Date:  1989-04-14       Impact factor: 47.728

6.  Trisomy 3 in low-grade B-cell lymphomas of mucosa-associated lymphoid tissue.

Authors:  A C Wotherspoon; T M Finn; P G Isaacson
Journal:  Blood       Date:  1995-04-15       Impact factor: 22.113

7.  A new chromosomal anomaly associated with mature B-cell chronic lymphoproliferative disorders: del(7)(q32).

Authors:  F Solé; S Woessner; L Florensa; S Montero; A Asensio; C Besses; J Sans-Sabrafen
Journal:  Cancer Genet Cytogenet       Date:  1993-02

8.  Cytogenetic studies in splenic lymphoma with villous lymphocytes.

Authors:  D G Oscier; E Matutes; A Gardiner; S Glide; S Mould; V Brito-Babapulle; J Ellis; D Catovsky
Journal:  Br J Haematol       Date:  1993-11       Impact factor: 6.998

9.  Homozygous deletions of 9p21 in primary human bladder tumors detected by comparative multiplex polymerase chain reaction.

Authors:  P Cairns; K Tokino; Y Eby; D Sidransky
Journal:  Cancer Res       Date:  1994-03-15       Impact factor: 12.701

10.  A (CA)n dinucleotide repeat assay for evaluating loss of allelic heterozygosity in small and archival human brain tumor specimens.

Authors:  D N Louis; A von Deimling; B R Seizinger
Journal:  Am J Pathol       Date:  1992-10       Impact factor: 4.307

View more
  21 in total

1.  Overall survival in aggressive B-cell lymphomas is dependent on the accumulation of alterations in p53, p16, and p27.

Authors:  M Sánchez-Beato; A I Sáez; I C Navas; P Algara; M Sol Mateo; R Villuendas; F Camacho; A Sánchez-Aguilera; E Sánchez; M A Piris
Journal:  Am J Pathol       Date:  2001-07       Impact factor: 4.307

2.  Primary splenic diffuse large B-cell lymphoma manifesting in red pulp.

Authors:  Makoto Kashimura; Masahiro Noro; Bunshiro Akikusa; Atsushi Okuhara; Shuji Momose; Ikuo Miura; Masaru Kojima; Jun-Ichi Tamaru
Journal:  Virchows Arch       Date:  2008-09-26       Impact factor: 4.064

3.  Splenic diffuse red pulp small B-cell lymphoma: revision of a series of cases reveals characteristic clinico-pathological features.

Authors:  George Kanellis; Manuela Mollejo; Santiago Montes-Moreno; Socorro-María Rodriguez-Pinilla; Juan C Cigudosa; Patricia Algara; Carlos Montalban; Estella Matutes; Andrew Wotherspoon; Miguel A Piris
Journal:  Haematologica       Date:  2010-03-10       Impact factor: 9.941

4.  Detection of BRAF mutations in patients with hairy cell leukemia and related lymphoproliferative disorders.

Authors:  Piers A Blombery; Stephen Q Wong; Chelsee A Hewitt; Alexander Dobrovic; Ellen L Maxwell; Surender Juneja; George Grigoriadis; David A Westerman
Journal:  Haematologica       Date:  2011-12-01       Impact factor: 9.941

5.  Constitutive expression of the AP-1 transcription factors c-jun, junD, junB, and c-fos and the marginal zone B-cell transcription factor Notch2 in splenic marginal zone lymphoma.

Authors:  Gunhild Trøen; Vigdis Nygaard; Tor-Kristian Jenssen; Ida Münster Ikonomou; Anne Tierens; Estella Matutes; Alicja Gruszka-Westwood; Daniel Catovsky; Ola Myklebost; Grete Lauritzsen; Eivind Hovig; Jan Delabie
Journal:  J Mol Diagn       Date:  2004-11       Impact factor: 5.568

6.  KLF2 mutation is the most frequent somatic change in splenic marginal zone lymphoma and identifies a subset with distinct genotype.

Authors:  A Clipson; M Wang; L de Leval; M Ashton-Key; A Wotherspoon; G Vassiliou; N Bolli; C Grove; S Moody; L Escudero-Ibarz; G Gundem; K Brugger; X Xue; E Mi; A Bench; M Scott; H Liu; G Follows; E F Robles; J A Martinez-Climent; D Oscier; A J Watkins; M-Q Du
Journal:  Leukemia       Date:  2014-11-27       Impact factor: 11.528

7.  Defining the borders of splenic marginal zone lymphoma: a multiparameter study.

Authors:  Scott D Dufresne; Raymond E Felgar; Rachel L Sargent; Urvashi Surti; Susanne M Gollin; Ellen D McPhail; James R Cook; Steven H Swerdlow
Journal:  Hum Pathol       Date:  2009-12-11       Impact factor: 3.466

8.  [Lymphomas of the spleen].

Authors:  A Marx; H K Müller-Hermelink; M Hartmann; E Geissinger; A Zettl; P Adam; T Rüdiger
Journal:  Pathologe       Date:  2008-03       Impact factor: 1.011

9.  [Splenic marginal zone B cell lymphomas].

Authors:  M M Ott; H K Müller-Hermelink
Journal:  Pathologe       Date:  2008-03       Impact factor: 1.011

10.  Splenic marginal zone lymphoma with villous lymphocytes shows on-going immunoglobulin gene mutations.

Authors:  Anne Tierens; Jan Delabie; Agnieszka Malecka; Junbai Wang; Alicja Gruszka-Westwood; Daniel Catovsky; Estella Matutes
Journal:  Am J Pathol       Date:  2003-02       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.